Autologous Macrophage Therapy for Liver Cirrhosis (MATCH): A First-in-Human, Phase 1, Single-Arm, Dose-Escalation Trial

被引：0
|
作者：
Moroni, Francesca [1 ]
Dwyer, Benjamin [1 ]
Glover, Alison [2 ]
Graham, Catriona [1 ]
Mcgowan, Neil [2 ]
Fraser, Alasdair [2 ]
Campbell, John [2 ]
Atkinson, Anne [2 ]
Mitchell, Donna [2 ]
Pass, Chloe [2 ]
Bailey, Laura [2 ]
Turner, Mark [2 ]
Hayes, Peter C. [3 ]
Fallowfield, Jonathan Andrew [4 ]
Forbes, Stuart J. [4 ]
机构：
[1] Univ Edinburgh, Ctr Regenerat Med, Edinburgh, Midlothian, Scotland
[2] NHS, Scottish Natl Blood Transfus Serv, London, England
[3] Univ Edinburgh, Ctr Inflammat Res, Edinburgh, Midlothian, Scotland
[4] Univ Edinburgh, Edinburgh, Midlothian, Scotland
来源：
HEPATOLOGY | 2018年 / 68卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
1979
引用
收藏
页码：1127A / 1128A
页数：2
相关论文
共 50 条
  • [21] Stereotactic Body Radiation Therapy to the Prostate Bed: Results of a Phase 1 Dose-Escalation Trial
    Sampath, Sagus
    Frankel, Paul
    del Vecchio, Bianca
    Ruel, Nora
    Yuh, Bertram
    Liu, An
    Tsai, Tsung
    Wong, Jeffrey
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2020, 106 (03): : 537 - 545
  • [22] ATRiUM: A first-in-human dose escalation phase I trial of ceralasertib (AZD6738) and gemcitabine as combination therapy.
    de Paula, Bruno Henrique
    Basu, Bristi
    Mander, Adrian
    Khan, Josephine
    Bundi, Purity
    Goodwin, Richard
    Thaventhiran, James
    Alberto, Gonzalez-Lopes
    Edmund, Godfrey
    Islam, Sabita
    Anand, Subha
    Evans, Jeff
    Graziano, Vincenzo
    Serrao, Eva
    Pawula, Maria
    Hernandez, Tatiana
    Dean, Emma
    Smith, Simon
    Jodrell, Duncan
    CANCER RESEARCH, 2021, 81 (13)
  • [23] Radioligand Therapy with 177Lu-EB-FAPI for the Treatment of Metastatic Radioiodine Refractory Thyroid Cancer: First-in-Human Dose-Escalation Clinical Trial
    Fu, H.
    Huang, J.
    Guo, W.
    Sun, L.
    Wu, H.
    Chen, H.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2023, 50 (SUPPL 1) : S174 - S174
  • [24] Phase 1, single-arm, open-label, dose escalation trial of microneedle array-doxorubicin in patients with mycosis fungoides
    Akilov, Oleg
    McCann, Sue
    Erdos, Geza
    Falo, Louis D.
    EUROPEAN JOURNAL OF CANCER, 2018, 101 : S32 - S32
  • [25] Phase 1, single-arm, open-label, dose escalation trial of microneedle array-doxorubicin in patients with mycosis fungoides
    Akilov, O. E.
    McCann, S.
    Chao, E. D.
    Cullison, S. Jackson
    Erdos, G.
    Falo, L. D., Jr.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2018, 138 (05) : S99 - S99
  • [26] Autologous macrophage therapy for liver cirrhosis: a phase 2 open-label randomized controlled trial
    Paul N. Brennan
    Mark MacMillan
    Thomas Manship
    Francesca Moroni
    Alison Glover
    Debbie Troland
    Iain MacPherson
    Catriona Graham
    Rhona Aird
    Scott I. K. Semple
    David M. Morris
    Alasdair R. Fraser
    Chloe Pass
    Neil W. A. McGowan
    Marc L. Turner
    Lynn Manson
    Neil J. Lachlan
    John F. Dillon
    Alastair M. Kilpatrick
    John D. M. Campbell
    Jonathan A. Fallowfield
    Stuart J. Forbes
    Nature Medicine, 2025, 31 (3) : 979 - 987
  • [27] First-in-human dose-escalation safety and PK trial of a novel intravenous humanized monoclonal CovX body inhibiting angiopoietin 2
    Rosen, L. S.
    Mendelson, D. S.
    Cohen, R. B.
    Gordon, M. S.
    Goldman, J. W.
    Bear, I. K.
    Byrnes, B.
    Perea, R.
    Schoenfeld, S. L.
    Gollerkeri, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [28] Safety and immunogenicity of a simian-adenovirus-vectored rabies vaccine: an open-label, non-randomised, dose-escalation, first-in-human, single-centre, phase 1 clinical trial
    Jenkin, Daniel
    Ritchie, Adam J.
    Aboagye, Jeremy
    Fedosyuk, Sofiya
    Thorley, Luke
    Provstgaad-Morys, Samuel
    Sanders, Helen
    Bellamy, Duncan
    Makinson, Rebecca
    Xiang, Zhi Quan
    Bolam, Emma
    Tarrant, Richard
    Lopez, Fernando Ramos
    Platt, Abigail
    Poulton, Ian
    Green, Catherine
    Ertl, Hildegund C. J.
    Ewer, Katie J.
    Douglas, Alexander D.
    LANCET MICROBE, 2022, 3 (09): : E663 - E671
  • [29] Safety and activity of RRx-001 in patients with advanced cancer: a first-in-human, open-label, dose-escalation phase 1 study
    Reid, Tony
    Oronsky, Bryan
    Scicinski, Jan
    Scribner, Curt L.
    Knox, Susan J.
    Ning, Shoucheng
    Peehl, Donna M.
    Korn, Ron
    Stirn, Meaghan
    Carter, Corey A.
    Oronsky, Arnold
    Taylor, Michael J.
    Fitch, William L.
    Cabrales, Pedro
    Kim, Michelle M.
    Burris, Howard A.
    Lao, Christopher D.
    Abrouk, Nacer E. D.
    Fanger, Gary R.
    Infante, Jeffrey R.
    LANCET ONCOLOGY, 2015, 16 (09): : 1133 - 1142
  • [30] SHR2554, an EZH2 inhibitor, in relapsed or refractory mature lymphoid neoplasms: a first-in-human, dose-escalation, dose-expansion, and clinical expansion phase 1 trial
    Song, Yuqin
    Liu, Yanyan
    Li, Zhi-Ming
    Li, Lanfang
    Su, Hang
    Jin, Zhengming
    Zuo, Xuelan
    Wu, Jianyuan
    Thou, Hui
    Li, Kunyan
    He, Chuan
    Zhou, Jianfeng
    Qi, Junyuan
    Hao, Siguo
    Cai, Zhen
    Li, Yijing
    Wang, Weiwei
    Zhang, Xiaojing
    Zou, Jianjun
    Zhu, Jun
    LANCET HAEMATOLOGY, 2022, 9 (07): : E493 - E503
12345